Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod - 12/08/11
Dallas and Houston, Texas
Abstract |
Epidermodysplasia verruciformis (EV) is a rare disorder characterized by widespread human papillomavirus infection and malignant transformation. EV may be caused by mutations of the genes EVER1 or EVER2, which are located on the EV1 locus, 17q25. We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CT, EV, HPV, SCC
Plan
Dr Berthelot is currently affiliated with the Department of Internal Medicine, University of Texas Health Science Center at Houston. Funding sources: None. Disclosure: Drs Tyring and Pandya are consultants, are clinical researchers, and serve on the speakers’ bureau for 3M Pharmaceuticals, maker of imiquimod. Drs Berthelot, Dickerson, Rady, He, and Niroomand have no conflicts of interest to declare. Presented in poster form at the American Academy of Dermatology 65th Annual Meeting, Washington, DC, February 2-6, 2007. Reprints not available from the authors. |
Vol 56 - N° 5
P. 882-886 - mai 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?